Healthcare -
Biotechnology - NYSE - US
$ 6.41
15.1 %
$ 372 M
Market Cap
-0.61
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Ginkgo Bioworks Holdings, Inc.
| Current Assets | 603 M |
| Cash & Short-Term Investments | 562 M |
| Receivables | 21.9 M |
| Other Current Assets | 19.3 M |
| Non-Current Assets | 775 M |
| Long-Term Investments | 48.7 M |
| PP&E | 598 M |
| Other Non-Current Assets | 128 M |
| Current Liabilities | 107 M |
| Accounts Payable | 14.2 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 93.1 M |
| Non-Current Liabilities | 554 M |
| Long-Term Debt | 439 M |
| Other Non-Current Liabilities | 115 M |
EFFICIENCY
Earnings Waterfall
Ginkgo Bioworks Holdings, Inc.
| Revenue | 227 M |
| Cost Of Revenue | 38.5 M |
| Gross Profit | 188 M |
| Operating Expenses | 748 M |
| Operating Income | -560 M |
| Other Expenses | -12.7 M |
| Net Income | -547 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Ginkgo Bioworks Holdings, Inc.
| Net Income | -547 M |
| Depreciation & Amortization | 63 M |
| Capital Expenditures | -62.5 M |
| Stock-Based Compensation | 112 M |
| Change in Working Capital | 0 |
| Others | 53 M |
| Free Cash Flow | -382 M |
Wall Street Analysts Price Targets
Ginkgo Bioworks Holdings, Inc.
Wall Street analysts predict an average 1-year price target for DNA of $7.06 , with forecasts ranging from
a
low of
$4.35 to a high of $12 .
DNA Lowest Price Target
Wall Street Target
4.35 USD
-32.14%
DNA Average Price Target
Wall Street Target
7.06 USD
10.11%
DNA Highest Price Target
Wall Street Target
12 USD
87.21%
4. DIVIDEND
ANALYSIS
DNA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Ginkgo Bioworks Holdings, Inc.
Sold
0-3 MONTHS
24 K USD 2
3-6 MONTHS
34.2 K USD 2
6-9 MONTHS
45 K USD 2
9-12 MONTHS
2.03 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
787 K USD 2
9-12 MONTHS
7. News
What's next for 23andMe and all that DNA data?
As 23AndMe files for bankruptcy, customers are left wondering what happens to their DNA data? On this episode of the Big Take podcast, we discuss what this means for millions of users' genetic data and for the future of the genetic testing industry.
youtube.com
- 1 week ago
Plex Research Partners With Ginkgo Bioworks on Artificial Intelligence (AI)-Powered Drug Discovery to Identify Novel Disease Mechanisms and Pathways
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Plex Research is partnering with Ginkgo Bioworks to use AI to deepen understanding of the mechanisms of action of existing drugs.
businesswire.com
- 2 weeks ago
Here's Why Ginkgo Bioworks (DNA) is Poised for a Turnaround After Losing -28.84% in 4 Weeks
The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
zacks.com
- 2 weeks ago
Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement
- Company Revamps Pharmacogenomics Go-To-Market Strategy, Targets Validated PGx Assay Towards Specific Use Cases - STONY BROOK, NY / ACCESS Newswire / April 1, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), its wholly-owned clinical laboratory subsidiary, is repositioning its TR8™ PGx pharmacogenomics testing service to offer tailored subpanels for indication-specific use cases in addition to full panel testing. The first subpanel under ADCL's new go-to-market strategy is for the pre-emptive testing of patients with genetic variants of the DPYD gene that correlate to potentially reduced or absent DPD enzyme activity necessary to metabolize fluoropyrimidines, specifically capecitabine (branded Xeloda) and fluorouracil (5-FU), two chemotherapy drugs that are widely used as part of the standard of care treatment for patients with certain cancers.
accessnewswire.com
- 2 weeks ago
23andMe bankruptcy: With America's DNA put on sale, market panic gets a new form of testing
The bankruptcy of consumer genetics testing company 23andMe last week led to widespread fears about the DNA of millions of Americans going on sale to the highest bidder. 23andMe has 15 million customers and with calls for users to delete their data, traffic to its website surged 526% on the day of its bankruptcy filing.
cnbc.com
- 3 weeks ago
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $6.59, denoting a -0.9% change from the preceding trading day.
zacks.com
- 3 weeks ago
24/7 Market News- Kraig Labs Makes History: World Record DNA Insertion Unlocks Massive Potential
Denver, Colorado--(Newsfile Corp. - March 27, 2025) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that Kraig Biocraft Laboratories' (OTCQB: KBLB) ("Kraig Labs") groundbreaking achievement-successfully inserting the largest functional DNA construct ever recorded into silkworms-is set to redefine what's possible in synthetic biology and biotechnology. This technological leap doesn't merely advance the science; it dramatically expands Kraig's potential to deliver next-generation materials and products to multiple high-value markets.
newsfilecorp.com
- 3 weeks ago
23andMe goes bankrupt, will now auction off DNA data
23andMe has proposed a May 14 auction for the sale of its assets, which include the genetic data of more than 15 million customers. The sale of genetic data raises concerns about privacy and safety, and customers are worried about what this means for their personal information.
youtube.com
- 3 weeks ago
Republic Bank Selects DNA From Fiserv to Drive Digital Transformation
MILWAUKEE--(BUSINESS WIRE)--Fiserv, Inc. (NYSE: FI), a leading global provider of payments and financial services technology, today announced that Republic Bank & Trust Company (Republic Bank) has chosen the Fiserv award-winning DNA® platform to enhance the company's banking system capabilities and drive operational efficiencies to realize their digital transformation goals. With over $6 billion in assets and 47 banking centers, Republic Bank, a community bank headquartered in Louisville, K.
businesswire.com
- 3 weeks ago
Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test
STONY BROOK, NY / ACCESS Newswire / March 26, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), the Company's wholly-owned clinical laboratory subsidiary, has submitted a validation package to the New York State Department of Health (NYSDOH) to request approval as a laboratory-developed test (LDT) for a PCR-based assay for the detection and subtyping of influenza A (H5) virus, also known as H5 bird flu, highly pathogenic avian influenza, or H5N1 (collectively "H5 bird flu"). ADCL's Linea™ Avian Influenza H5 Dx assay ("AIH5 Dx") is a highly sensitive, multi-target diagnostic assay capable of detecting and discriminating between pan-influenza A and H5 bird flu.
accessnewswire.com
- 3 weeks ago
23andMe has filed for bankruptcy. What does this mean for your DNA data privacy?
The genetic testing company 23andMe has filed for bankruptcy, prompting people who've used the service and sent in DNA samples to be analyzed to wonder what will happen to their genetic data.
techxplore.com
- 3 weeks ago
DNA testing pioneer 23andMe files for bankruptcy as concerns mount over data privacy of 15M customers
DNA testing pioneer 23andMe filed for bankruptcy — sparking fresh concerns about safeguarding the personal data of the company's more than 15 million customers.
nypost.com
- 3 weeks ago
8. Profile
Summary
Ginkgo Bioworks Holdings, Inc. DNA
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 372 M
Dividend Yield
0.00%
Description
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Contact
27 Drydock Avenue, Boston, MA, 02210
https://www.ginkgobioworks.com
IPO
Date
April 19, 2021
Employees
834
Officers
Ms. Karen Tepichin
General Counsel & Secretary
Mr. Mark E. Dmytruk
Chief Financial Officer
Mr. Steven P. Coen CPA
Chief Accounting Officer
Mr. Austin Che Ph.D.
Founder, Head of Strategy & Treasurer
Mr. Bartholomew Canton Ph.D.
Founder, Chief Technology Officer & Secretary
Ms. Samantha Sutton
Head of People
Mr. Joshua Dunn
Head of Design
Dr. Jason Kelly Ph.D.
Founder, Chief Executive Officer & Director
Dr. Reshma P. Shetty
Founder, President, Chief Operating Officer & Director
Mr. Thomas Knight Jr.
Founder